Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis

Area of Science:

• Immunology and Dermatology
• Epigenetics and Molecular Biology

Background:

• Scleroderma (SSc) is an autoimmune disease causing skin fibrosis with no effective treatments.
• Epigenetic modifications, particularly methylation, are implicated in fibroblast activation and SSc pathogenesis.

Purpose of the Study:

• To investigate the role of methyl cap binding protein-2 (MeCP2) in SSc-associated fibrosis.
• To explore MeCP2's mechanism in regulating extracellular matrix production and cellular metabolism.

Main Methods:

• Utilized normal and SSc dermal fibroblasts.
• Employed small interfering RNA silencing and lentiviral overexpression to manipulate MeCP2 levels.
• Quantified MeCP2 and microRNA-132 (miRNA132) expression using immunoblotting and real-time PCR.

Main Results:

• SSc fibroblasts exhibit elevated basal MeCP2 levels, induced by TGF-β1 in normal cells.
• MeCP2 upregulates extracellular matrix via epigenetic repression of sFRP-1, enhancing Wnt signaling.
• Fibrosis is mediated through glycolysis; inhibiting glycolysis reduces Wnt-induced collagen expression, and miR132 is downregulated in SSc fibroblasts.

Conclusions:

• An epigenetic regulatory loop involving MeCP2 drives SSc fibrosis.
• Targeting MeCP2, a key epigenetic regulator, presents a potential therapeutic strategy.
• Modulating the metabolic reprogramming via aerobic glycolysis is another promising therapeutic avenue for SSc.